Actinium-225 Lintuzumab (225Ac-Actimab-A™), a monoclonal antibody targeting CD33, is a groundbreaking treatment for AML and potentially other cancers. Demonstrating tolerability and significant antileukemia activity in clinical trials, this innovative drug, with its specific targeting and potent alpha particle radiation, offers new hope for patients, particularly those ineligible for conventional therapies. Its development signifies a significant advancement in targeted cancer therapies, with ongoing research expanding its potential applications.
Understanding Actinium-225 Lintuzumab
The development of Actinium-225 Lintuzumab (225Ac-Actimab-A™, 225Ac-DOTA-huM195) marks a significant milestone in the treatment of acute myeloid leukaemia (AML), one of the most challenging forms of leukaemia to treat. This innovative drug, based on a monoclonal antibody targeting CD33, offers new hope for patients, particularly those above 60 years old, who often do not qualify for traditional chemotherapy.
225Ac-Lintuzumab-A™ is a product of advanced medical research, combining a 225Ac-labelled monoclonal antibody with Lintuzumab (huM195), the humanised version of the older M195 mouse antibody. The CD33 antigen, targeted by this drug, is commonly found on myeloid leukaemia cells, making it a specific and effective treatment option.
The Challenge of AML
AML is notoriously difficult to treat, especially in older patients. Standard chemotherapy regimens are often unsuitable for this age group, and the median survival rate following diagnosis is approximately two months without treatment. This grim prognosis underscores the urgent need for more effective and accessible treatment options.
Clinical Trials and Results
The journey of 225Ac-Lintuzumab-A™ through clinical trials has been promising. A Phase I/II multi-center AML trial involved 21 patients in Phase I (escalating dose) and 53 in Phase II. Results showed that Lintuzumab-A was tolerable and demonstrated significant antileukemia activity. These encouraging outcomes have opened the door for further research and potential wider application.
Expanding the Scope
Beyond AML, metastatic colon cancer is the next indication for exploration with 225Ac-Lintuzumab-A™. The versatility of this drug is further underscored by its ongoing trials for refractory multiple myeloma, initiated in December 2016. In June 2018, a new clinical trial began to study the effects of Actimab-A on minimal residual disease in post-remission AML patients, highlighting its potential for broader use in oncology.
Two new clinical studies were initiated in 2019, with patient recruitment shifted to 2021 in combination with Venetoclax. Expected completion is in 2023-2024. These studies represent a significant step in understanding the full potential of 225Ac-Lintuzumab in combination therapies.
Broadening the Horizon
The developer is considering expanding the drug’s application to other cancers, notably under the names Actimab-B for colon cancer and Actimab-P for prostate cancer. This strategic move could transform Actinium-225 Lintuzumab from a leukemia-focused treatment to a versatile weapon against various cancer types.
Target and Mechanism
The key to 225Ac-Lintuzumab’s effectiveness lies in its target the CD33 antigen. This specificity allows for a more focused approach in attacking leukaemia cells. Additionally, the use of alpha particle radiation in this drug offers a potent and precise method to destroy cancer cells while minimising damage to surrounding healthy tissues.
Carrier and Ligand
Lintuzumab is the carrier and ligand in this therapeutic equation, which is crucial in directing the alpha particles to the cancer cells. This harmonious combination of targeted therapy and potent radiation presents a new paradigm in cancer treatment.
Actinium-225 Lintuzumab represents a beacon of hope in the fight against AML and potentially other forms of cancer. Its targeted approach, combined with the power of alpha particle radiation, offers a promising alternative to traditional chemotherapy, especially for older patients who face limited treatment options.You Are Here: Home »